









Markets
/
Stocks
/
nasdaq-nxgl
/

Nexgel Inc

NXGL

2.360USD

+0.160+7.27%

Close 11/05, 16:00（ET）Quotes delayed by 15 min

18.06MMarket Cap

LossP/E TTM



Nexgel Inc

2.360

+0.160+7.27%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Nexgel Inc

Currency: USD Updated: 2025-11-04

Key Insights

The company's fundamentals are relatively stable. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a very weak market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Nexgel Inc's Score

Industry at a Glance

Industry Ranking

100 / 159

Overall Ranking

257 / 4616

Industry

Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 1 analysts

Buy

Current Rating

6.000

Target Price

+155.32%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Nexgel Inc Highlights

StrengthsRisks

NexGel, Inc. is a provider of healthcare, beauty, and over-the-counter products, including ultra-gentle, high-water-content hydrogels. It is engaged in manufacturing high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels, used for wound care, medical diagnostics, transdermal drug delivery and cosmetics. It specializes in custom gels by capitalizing on proprietary manufacturing technologies. Its Nexgel segment comprises the manufacturing of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, which is based in Langhorne, Pennsylvania. Its CG labs segment comprises the CG Converting and Packaging, LLC used for the Company’s converting and packaging business, which is based in Granbury, Texas. Its hydrogel consumer products are marketed under the brand names MedaGel and LumaGel Beauty. Its brands include Silverseal, Hexagels, Turfguard, Kenkoderm, and Dermablock. It also specializes in eye and eyelash consumer products.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 324.22% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 8.69M.

Undervalued

The company’s latest PE is -5.50, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 711.63K shares, decreasing 1.57% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 68.65K shares of this stock.

Financial Health

Currency: USD Updated: 2025-11-04

The company's current financial score is 6.53, which is lower than the Pharmaceuticals industry's average of 7.76. Its financial status is weak, and its operating efficiency is average. Its latest quarterly revenue reached 2.88M, representing a year-over-year increase of 100.28%, while its net profit experienced a year-over-year increase of 24.86%.

Score

Industry at a Glance

Previous score

6.53

Change



Financials

5.94

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.26

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

7.15

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

5.19

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.13

Key Metrics

Free cash flow

No Data

Nexgel Inc's Company Valuation

Currency: USD Updated: 2025-11-04

The company’s current valuation score is 7.43, which is higher than the Pharmaceuticals industry's average of 7.21. Its current P/E ratio is -5.50, which is -72.46% below the recent high of -1.52 and -60.85% above the recent low of -8.85.

Score

Industry at a Glance

Previous score

7.43

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 100/159

No Data

Earnings Forecast

Currency: USD Updated: 2025-11-04

The company’s current earnings forecast score is 8.00, which is higher than the Pharmaceuticals industry's average of 7.77. The average price target for Nexgel Inc is 6.00, with a high of 6.00 and a low of 6.00.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

No Data

Analyst Rating

Based on 1 analysts

Buy

Current Rating

6.000

Target Price

+172.71%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

169

Total

Median

Average

Company name

Ratings

Analysts

Nexgel Inc

NXGL

Biogen Inc

BIIB

Amgen Inc

AMGN

Vertex Pharmaceuticals Inc

VRTX

Eli Lilly and Co

LLY

AbbVie Inc

ABBV

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-04

The company’s current price momentum score is 6.38, which is lower than the Pharmaceuticals industry's average of 6.89. Sideways: Currently, the stock price is trading between the resistance level at 2.66 and the support level at 1.97, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.58

Change

-0.2

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(4)

Neutral(2)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.074

Sell

RSI(14)

44.587

Neutral

STOCH(KDJ)(9,3,3)

20.114

Neutral

ATR(14)

0.173

Low Volatility

CCI(14)

-130.240

Sell

Williams %R

73.842

Sell

TRIX(12,20)

-0.110

Sell

StochRSI(14)

76.850

Buy

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

2.374

Sell

MA10

2.466

Sell

MA20

2.525

Sell

MA50

2.472

Sell

MA100

2.474

Sell

MA200

2.648

Sell

Institutional Confidence

Currency: USD Updated: 2025-11-04

The company’s current institutional recognition score is 3.00, which is lower than the Pharmaceuticals industry's average of 5.74. The latest institutional shareholding proportion is 8.74%, representing a quarter-over-quarter decrease of 62.98%. The largest institutional shareholder is The Vanguard, holding a total of 68.65K shares, representing 0.84% of shares outstanding, with 28.86% increase in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Stein (John Nachum)

461.46K

-9.46%

Levy (Adam R)

371.34K

-1.07%

Evernest Financial Advisors, LLC

281.00K

+25.07%

Glassman (steven mark)

156.66K

+0.03%

Morgan Stanley Smith Barney LLC

121.55K

+38.44%

Henry (Scott Robert)

121.36K

-5.96%

Zeldis (Jerome B)

106.66K

The Vanguard Group, Inc.

Star Investors

68.65K

+37.02%

Geode Capital Management, L.L.C.

66.37K

-0.12%

Renaissance Technologies LLC

Star Investors

54.83K

-32.83%

Risk Assessment

Currency: USD Updated: 2025-11-04

The company’s current risk assessment score is 2.90, which is lower than the Pharmaceuticals industry's average of 5.15. The company's beta value is 0.57. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.